Human Medicine:

The Christie Pathology Partnership Begins Offering VENTANA PD-L1 (SP142) Assay as Companion Diagnostic Test in Bladder Cancer Patients

Published: 22nd May 2019

Following NICE approval in December 2018 a companion diagnostic test is required to determine PD-L1 levels in the tumour tissue of cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer prescribed treatment with pembrolizumab (Keytruda) or atezolizumab (Tecentriq).  PD-L1 testing is funded by NHS England as described in 2017/19 National Tariff High Cost Devices.

The Christie Pathology Partnership (CPP) is one of the first reference laboratories to offer the new companion test. The Ventana PD-L1 (SP142) Assay won FDA approval in July 2018 as a companion diagnostic test to select patients for treatment with atezolizumab. The SP142 assay determines PD L1 expression in immune cells, and the agency requires PD-L1 stained tumour-infiltrating immune cells covering greater ≥5% of the tumour area to be eligible for atezolizumab monotherapy.

“We are pleased to add this companion test to our diagnostic testing services which will enable clinical teams to treat patients with urothelial cancers with newer therapeutic options,” said Dr Pedro Oliveira, Consultant Pathologist at The Christie NHSFT.

Roche also announced last week that it had received FDA approval of the PD-L1 (SP142) assay in identifying triple negative breast cancer patient eligible for atezolizumab plus chemotherapy.

Sue Clark, CPP General Manager said “We are also hugely excited by the addition of the assay to our 2019 pipeline. PD-L1 (SP142) testing in triple negative breast cancer is planned as part of an Early Access to Medicines Scheme (EAMS) approved by MHRA and we plan to be one of the first UK reference laboratories to offer this test”.

For more information please contact [email protected]

The Christie Pathology Partnership

The Christie Pathology Partnership (CPP) is unique joint venture between The Christie NHSFT, Europe’s largest single site cancer centre and SYNLAB, Europe’s largest laboratory provider.  CPP is UKAS accredited to ISO15189 standards offering blood sciences including specialist oncology biochemistry and flow cytometry, cytogenetic analysis, fluorescence in-situ hybridization (FISH), immunohistochemistry and stem cell processing. CPP is fully accredited to ISO-15189.

Latest Human Medicine News
Important statement: Pathology First

Published: 24th June 2022 We are aware that, in recent days, a media report has been published regarding our Pathology First partnership with Mid and…

Read More (about 'Important statement: Pathology First')
Pathology laboratory becomes the first in the UK to support remote plate reading  

Published: 15th June 2022 A pathology laboratory is leading the way in speeding up access to patient care and treatment after becoming the first in…

Read More (about 'Pathology laboratory becomes the first in the UK to support remote plate reading  ')
SYNLAB UK & Ireland to showcase biomedical science career opportunities during IBMS Congress

Published: 10th March 2022 Leading pathology provider SYNLAB UK & Ireland is looking forward to welcoming biomedical scientists to its stand at the IBMS Congress…

Read More (about 'SYNLAB UK & Ireland to showcase biomedical science career opportunities during IBMS Congress')
Case Studies

Published: 19th August 2021 At SYNLAB we are very proud of the services we provide with our NHS partners. Our involvement has enabled the service…

Read More (about 'Case Studies')
Stella with Staff
Hares About Town

Published: 23rd July 2021 Pathology First Sponsors Stella, The Disco Hare Pathology First is the proud sponsor of Stella the Disco Hare as part of…

Read More (about 'Hares About Town')
New Pathology Partnership to Transform Patient Care in UK Capital

Published: 1st April 2021 A partnership that will transform pathology services and help to improve the quality of patient care across South East London has…

Read More (about 'New Pathology Partnership to Transform Patient Care in UK Capital')